ObsEva Announces Publication of Abstracts from Phase 2b EDELWEISS Trial of Linzagolix in Endometriosis
Significant improvement in quality of life outcomes maintained or increased after 52 weeks of treatment with linzagolix Small, expected, non-clinically relevant increases in serum lipids observed at 12 weeks generally stable at 52 weeks GENEVA, …